NAYA Therapeutics, a US-based clinical-stage biopharmaceutical company developing next-generation cancer therapies, has entered into a research and manufacturing partnership with China’s Alpha Nuclide, a radiopharmaceutical solutions company leading global efforts in Astatine-211 (211At) supply and CDMO services.   

Under the agreement, Alpha Nuclide will supply NAYA with 211At produced at its East China production facility near Shanghai. The collaboration will also support investigator-initiated clinical trials in China in 2026 for NY-703, NAYA’s GPC3-targeting 211At alpha therapy designed to treat residual disease and metastasis in hepatocellular carcinoma (HCC).

Commenting on the partnership, Dr. Daniel Teper, CEO of NAYA Therapeutics, said, "We are excited to partner with Alpha Nuclide, a leader in Astatine-211 research and manufacturing. Their growing facilities and deep understanding of the precision manufacturing and supply chain logistics for Astatine-211 make them an ideal partner for advancing our programmes.”

"Access to the China market and its large HCC population is critical to accelerating initial data readouts for NY-703 prior to expanding development to patients in the US and Europe. We see Alpha Nuclide's supply chain solutions in China as a validating model for future global expansion of Astatine-211 radiopharmaceuticals,” he added.

Dr. Yutian Feng, CEO of Alpha Nuclide, called the collaboration with NAYA Therapeutics an important step towards accelerating the development of Astatine-211 targeted alpha therapies.

"Astatine-211 is increasingly recognised as an optimal, ‘goldilocks’ alpha-particle emitter with highly-attractive properties including a short half-life, clean decay, minimal toxicity, and potential for broad supply, overcoming the limitations over other radionuclides and unlocking the potential of alpha therapies to address the needs of cancer patients at risk of residual disease & metastasis,” Dr. Feng stated.  

This agreement builds on NAYA’s recent partnerships with Ionetix and Atley Solutions, as the company continues to strengthen its decentralised 211At supply network and consolidate its early-mover advantage in the targeted alpha therapy space.